Why We Created Beacon
Battling the devastating effects that glaucoma can have on individuals, and the limits and barriers it can place on living an everyday life, Dr. J David Brown was inspired to pursue a better treatment for patients and physicians. Building on his groundbreaking work, MicroOptx developed the Beacon device. We believe wholeheartedly that individuals with glaucoma have suffered enough and that treatments for this disease should ease suffering. So, we’ve been thinking big by thinking small. We carefully conceived and engineered the Beacon device to not only be an effective treatment, but one that is safe, minimally invasive and can be simply implanted with little to no pain caused to the patient. Current clinical trials are underway to evaluate Beacon’s safety and effectiveness.
An Improved Outlook for Glaucoma Treatments
The treatment of glaucoma has been stuck in time, with the most common surgical interventions such as tube shunt technologies and trabeculectomy procedures claiming origins of development in 1969.
Over the past decade, minimally invasive glaucoma surgical devices (MIGS) have emerged as a promising mode of glaucoma treatment, and several MIGS devices are available or in varying stages of the US and European regulatory cycle. Though each utilizes unique materials, they all share one fundamental trait – they are shunting excess aqueous humor from the anterior chamber to one of three enclosed spaces in and around the eye: sub-conjunctival space, Schlemm’s canal, or the suprachoroidal space.
Because all these implants are completely enclosed, the resultant IOP associated with shunting internal to the eye is physiologically limited by the venous pressure inside the eye and can also be affected by the recumbent nighttime episcleral venous pressure increase that may contribute to nighttime increases in IOP1.
1. Pillunat, Lutz E., et al. “Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents.” Clinical Ophthalmology (Auckland, NZ) 11 (2017): 1583.